Somewhat Positive Press Coverage Somewhat Unlikely to Impact Mesoblast Limited (MESO) Share Price
Media stories about Mesoblast Limited (NASDAQ:MESO) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mesoblast Limited earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.4781928659181 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Mesoblast Outlines Potential Pathway to Accelerated Market Entry for MPC-150-IM in Advanced Chronic Heart Failure – GlobeNewswire (press release) (globenewswire.com)
- Keep Your Active Eyes on Mesoblast Limited (MESO) – Wall Street Morning (wallstreetmorning.com)
- Middle East and Africa Stem Cell Market Size, Share, Trends and Forecast to 2021 (emailwire.com)
Mesoblast Limited (NASDAQ MESO) opened at 6.49 on Friday. Mesoblast Limited has a one year low of $4.01 and a one year high of $12.50. The firm’s market capitalization is $516.24 million. The firm has a 50-day moving average price of $7.24 and a 200 day moving average price of $8.23.
Several equities research analysts have recently commented on the company. Cantor Fitzgerald reissued a “buy” rating on shares of Mesoblast Limited in a research note on Wednesday. Maxim Group set a $14.00 target price on Mesoblast Limited and gave the company a “buy” rating in a research note on Wednesday, August 16th. Zacks Investment Research raised Mesoblast Limited from a “sell” rating to a “buy” rating and set a $10.00 target price on the stock in a research note on Tuesday, May 23rd. BidaskClub lowered Mesoblast Limited from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Finally, Credit Suisse Group set a $11.00 target price on Mesoblast Limited and gave the company a “hold” rating in a research note on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. Mesoblast Limited currently has a consensus rating of “Hold” and an average target price of $12.70.
WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Mesoblast Limited (MESO) Share Price” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/08/25/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-mesoblast-limited-meso-share-price.html.
Mesoblast Limited Company Profile
Receive News & Stock Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related stocks with our FREE daily email newsletter.